Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
‍
Are you a health professional practicing in the United States?
Yes, take me to Medical Affairs
No, Take me to ParatekPharma.com

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Medical Information Request
Publications & Presentations
Grants & Funding
Product Resources
Disease Education Resources
Medical Affairs
Publications & Presentations

Publications & Presentations

Paratek is committed to enhancing public health through responsible sharing of clinical trial data.

This page contains links to publications and access to congress presentations  related to our products and may contain information regarding approved and non-approved uses, formulations, or treatment regimens. Information provided is not intended to promote any product or indication. Results reported in any single study may not reflect the overall results obtained across the product development.

Please see the Full Prescribing Information available here.

Download a complete bibliography with links to publications and presentations here.

Manuscript Icon
Manuscripts
Poster Icon
Posters

Manuscripts

Explore Paratek's Manuscripts below.

Filters
Clear all
Filter By Category
Clear
Search by Citation
Clear
Areas of Interest
Clear
Clear all
Apply
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters Publications and Manuscripts
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Non-Clinical
Omadacycline Potentiates Clarithromycin Activity Against Mycobacterium abscessus
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Hanh
Citation #
13191:27:00
Date
December 2021
Microbiology
Surveillance of Omadacycline Activity Tested Against Clinical Isolates from the USA: Report from the SENTRY Antimicrobial Surveillance Program, 2019
Resource Type
Manuscript
Areas of Interest
ABSSSI & CABP
Author Name
Pfaller
Citation #
337-351
Date
December 2021
Microbiology
Novel Tet(L) Efflux Pump Variants Conferring Resistance to Tigecycline and Eravacycline in Staphylococcus Spp.
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Wang
Citation #
9(3):e0131021
Date
December 2021
Microbiology
In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Camporeale
Citation #
9(2):e0144021
Date
October 2021
Pharmacokinetics - Pharmacodynamics
Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant Enterococcus faecium Meningitis and Bacteremia
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Wenzler
Citation #
13(3):843-854
Date
September 2021
Non-Clinical
Efficacy of Omadacycline Against Multiresistant Enterococcus faecium Strains in a Mouse Peritonitis Model
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Singh
Citation #
65(9):e00709-21
Date
August 2021
Clinical
Safety and Efficacy of Omadacycline by Body Mass Index in Patients with Community-Acquired Bacterial Pneumonia: Subanalysis from a Randomized Controlled Trial
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Pai
Citation #
1958:02:00
Date
August 2021
Microbiology
In Vitro Susceptibility of Rickettsia Species to Eravacycline, Omadacycline and Tigecycline
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Quade
Citation #
65(8):e00665-21
Date
July 2021
Guideline
Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response
Resource Type
Manuscript
Areas of Interest
Biothreats
Author Name
Nelson
Citation #
70(No. RR-3):1-27
Date
July 2021
Clinical
Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community‐acquired Bacterial Pneumonia by Disease Severity: Results from the OPTIC Study
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Ramirez
Citation #
8 (6):ofab135
Date
June 2021
Non-Clinical
Efficacy of Omadacycline Against Escherichia coli in a Mouse UTI Model
Resource Type
Manuscript
Areas of Interest
Urinary Tract Infections
Author Name
Singh
Citation #
65(7):e00269-21
Date
June 2021
Microbiology
In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Sun
Citation #
41: 293-301
Date
May 2021
Clinical
Safety and Efficacy of Omadacycline by BMI Categories and Diabetes History in Two Phase III Randomized Studies of Patients with Acute Bacterial Skin and Skin Structure Infections
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Pai
Citation #
76(5): 1315-1322
Date
April 2021
Clinical
Omadacycline versus Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Torres
Citation #
104(2021): 501-509
Date
March 2021
Microbiology
In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria (NTM)
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Brown-Elliott
Citation #
65(3): e01947-20
Date
February 2021
Microbiology
Activity of Omadacycline and Other Tetracyclines Against Contemporary Gram-Negative Pathogens from New York City Hospitals
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Iregui
Citation #
27(2): 190-195
Date
February 2021
Pharmacokinetics - Pharmacodynamics
In Vitro Pharmacodynamics of Omadacycline against Escherichia coli and Acinetobacter baumannii
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Noel
Citation #
76(3): 667-670
Date
February 2021
Show More Resources
No results found.
There are no results with this criteria. Try changing your search.

Posters

Explore Paratek's Publications below.

2024
ASM Microbe
accordio_arrow
ASM Microbe 2024
ATS
accordio_arrow
ATS
MAD-ID
accordio_arrow
MAD-ID 2024
ESCMID Global (formally ECCMID)
accordio_arrow
ESCMID Global (formally ECCMID)
Texas Medical Center AMR & Stewardship
accordio_arrow
Texas Medical Center AMR & Stewardship
2023
ECCMID
accordio_arrow
ECCMID 2023
ASM Microbe
accordio_arrow
ASM Microbe 2023
IDWeek
accordio_arrow
IDWeek 2023
2022
CO Mycobacterium Conference
accordio_arrow
CO Mycobacterium Conference
MAD-ID
accordio_arrow
MAD-ID 2022
ASM-Microbe
accordio_arrow
ASM-Microbe 2022
MHSRS
accordio_arrow
MHSRS 2022
IDWeek
accordio_arrow
IDWeek 2022
International Symposium for Hidradenitis Suppurativa Advances
accordio_arrow
International Symposium for Hidradenitis Suppurativa Advances
2021
IDWeek
accordio_arrow
IDWeek 2021
2020
IDWEEK
accordio_arrow
IDWEEK 2020
2019
ASM-ESCMID
accordio_arrow
ASM-ESCMID 2019
IDWEEK
accordio_arrow
IDWEEK 2019
ECCMID
accordio_arrow
ECCMID 2019
View All
Evaluation of Omadacycline Treatment for Osteomyelitis
In Vitro Interaction of Omadacycline in Combination with Melatonin against Carbapenemase producing Klebsiella pneumoniae
Omadacycline as Salvage Therapy for Pulmonary Mycobacterium Abscessus Complex
Minimum inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline
Omadacycline alone and in combination as a treatment option for Mycobacterium avium infections
​​Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury (ALI)
Real-World Outpatient Use of Omadacycline for Bone and Joint Infections
Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)
High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019–2021)
Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections
A Functional OMICS Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review
Omadacycline Efficacy in a Post-Exposure Prophylaxis Mouse Model of Inhalational Anthrax Caused by Ciprofloxacin-Resistant Bacillus anthracis
Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in New Zealand White Rabbits
In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programmme
Gut microbiome diversity and bacterial taxonomic group changes in healthy volunteers receiving oral omadacycline or vancomycin
AMR register: creation of a new, freely accessible platform for antimicrobial susceptibility data sharing
Quantifying antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacteria infections: an opportunity for novel agents?
Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)
A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
Bile Acid Concentrations in Healthy Volunteers Receiving Oral Omadacycline or Vancomycin
Preclinical evaluation of omadacycline for potential as a drug to treat Acinetobacter baumannii and Klebsiella pneumoniae infections in combat wounds
In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars
Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease
Clinical Response to Intravenous versus Oral Treatment in Patients with Acute Bacterial Skin and Skin Structure Infections
Omadacycline is not a Substrate for Clinically Relevant Beta-Lactamase Enzymes
Omadacycline in Vitro Activity Against Bacillus anthracis
Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria
Assessment of Pharmacokinetics-Pharmacodynamics to Support Omadacycline Dosing Regimens for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
No items found.
No items found.
No items found.

Contact Us

If you would like to speak to a Paratek Medical Information Professional please call 1-833-PARATEK (1-833-727-2835) or email medinfo@paratekpharma.com. Otherwise please see below.

MSD Contact Form
Cancel
Thank you! Your submission has been received!
Close
Oops! Something went wrong while submitting the form.

By completing this form, I verify that I requested this information completely independently and solely for my own evaluation and application to my practice, patients, or general education, or for the pharmacy and therapeutics committee. I affirm that my request was in no way prompted by Paratek Pharmaceuticals or any representative of Paratek.

Medical Information
If you would like to speak to a Paratek Medical Information Professional please call Paratek Customer Service at 1-833-PARATEK (1-833-727-2835) (Monday to Friday, 8 AM to 8 PM ET, excluding holidays) or email medinfo@paratekpharma.com
Submit an Inquiry
Report a Product Complaint
To report a Product Quality Complaint for a Paratek product, please call 1-833-Paratek (1-833-727-2835).
Report an Adverse Event
To report an Adverse Event for a Paratek product, please fill out a form or call us 1-833-PARATEK (1-833-727-2835). You can also contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Submit an Adverse Event Report
Request follow-up from a Medical Science Director
If you would like additional information about our products or would like to discuss research ideas, please contact our MSD team.
Contact an MSD

Privacy Policy | Terms and Conditions | Social Media Guidelines | Compliance Program | Expanded Access Policy

© 2024 Paratek Pharmaceuticals, Inc. All rights reserved. PARATEK® and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA® and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc.

US-COR-0050-01 06/24